Metagenomics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 12.60 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Metagenomics Market Analysis
The metagenomics market is expected to register a CAGR of 12.6% over the forecast period.
- The COVID-19 pandemic significantly impacted the metagenomics market due to the growing demand for effective therapeutics, leading to the market's growth. For instance, according to an article published by BioMed Central (BMC) Infectious Diseases in October 2022, sequence-independent metagenomic sequencing was used to determine the whole virome in patients infected with SARS-CoV-2 and to explore whether there could be a correlation between the presence of viruses other than SARS-CoV-2, and severity of the disease. Viral metagenomics approaches were considered semi-quantitative. With such utilization of metagenomic sequence for determining the virus, its demand increases, thereby driving the market growth. Furthermore, the emergence of new variants and the ongoing need for monitoring and surveillance may continue to drive demand for metagenomic technologies, presenting both challenges and opportunities over the forecast period.
- Factors such as increasing R&D expenditure, declining sequencing expenses, and technological advancements are expected to drive market growth over the forecast period. For instance, in September 2022, the UK Government reported that expenditure on pharmaceutical research performed in UK businesses was EUR 5 billion (USD 5.9 billion). This was 18.6% of total expenditure on R&D in industries, significantly more than any other product group. Of the EUR 5 billion (USD 5.9 billion) spent on pharmaceutical R&D performed in businesses, EUR 3.8 billion (4.84 billion) was from the businesses themselves, EUR 1 billion (USD 1.14 billion) was from overseas, and EUR 12 million (USD 14.6 million) was from the government. Pharmaceuticals were 13th of 33 product groups by level of government funding for R&D performed in businesses.
- Furthermore, the increased launch of technologically advanced metagenomics platforms is expected to propel market growth. For instance, in October 2022, SYNLAB and Microba Life Sciences (Microba) expanded their strategic agreement to broaden the geographic and market availability of the microbiome test myBIOME across Europe and Latin America. Applying game-changing metagenomic technology developed by Microba, myBIOME detects all types of microorganisms (bacteria, archaea, fungi, protists), identifies the exact species, and characterizes new species.
- Thus, factors such as increasing R&D expenditure, declining sequencing expenses, and technological advancements are expected to drive the market's growth during the forecast period. However, the high cost of metagenomic sequencing is expected to hamper the market to a certain extent over the forecast period.
Metagenomics Market Trends
Sequencing and Data Analytics Services Segment is Expected to Witness Healthy Growth Over the Forecast Period
- Metagenomics sequencing and data analytics services are the processes of sequencing all genetic material in a biological sample. Metagenomics sequencing and data analytics services data boost the power of protein modeling software to yield hundreds of new protein structure predictions. The segment is being driven by factors such as the increasing applications of metagenomic sequence, speed, cost, accuracy, efficient replacement of traditional technologies, and drug discovery applications demanding metagenomic sequencing technology.
- The advantage of this technology is that it is significantly cheaper, quicker, and requires significantly less deoxyribonucleic acid (DNA), which helps in the overall growth of the segment. For instance, according to research presented by the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in April 2023, metagenomic sequencing provides rapid and actionable antimicrobial resistance predictions to treat bloodstream infections much faster than conventional laboratory tests and has the potential to save lives and better manage the use of antibiotics. Hence, the advantage associated with metagenomic sequencing and data analytics services is expected to drive segmental growth.
- Various technological advancements in the field of medicine are growing at a rapid pace and have led to segmental growth. For instance, in December 2022, Novogene launched the inclusion of clinical whole genome sequencing (WGS) under their ISO 17025 certification. This follows on from the ISO 17025 accreditation awarded to Novogene's Cambridge lab for clinical whole exome sequencing (WES) in 2021.
- Thus, factors such as increasing applications of metagenomic sequence and drug discovery applications demanding metagenomic sequencing technology will likely contribute to the segment's growth over the forecast period.
North America is Expected to Hold a Significant Share of the Market Over the the Forecast Period
- North America is expected to hold a significant market due to the presence of many pharmaceutical and biotechnological companies working toward establishing novel and efficient metagenomic platforms, along with the increasing research and development expenditure by the key players.
- Also, the wide adoption of metagenomics diagnostic and an increasing number of next-generation sequencing (NGS)-based research and technological advancements are driving the studied market in the region. For instance, in June 2023, Delve Bio debuts with USD 35 million in Series A financing led by Perceptive Xontogeny Venture Fund II (PXV Fund II) and joined by Section 32 and GV. The funds were used to commercialize the company's mNGS-based infectious disease test, which infectious disease experts developed at the University of California San Francisco (UCSF) Center for Next-Gen Precision Diagnostics and advance a pipeline of next-generation tests.
- Additionally, the increase in pharmaceutical R&D is driving the growth of the studied market. For instance, in September 2022, a report published by the International Trade Administration (ITA) stated that Mexico's 2022 budget planning includes a 14.6% increase in health sector resources to prioritize first and second-level care for high-specialty diseases, such as diabetes, cancer, and heart disease. Thus, an increase in the healthcare resource budget contributed to the increase in pharmaceutical R&D, thereby driving regional growth over the forecast period.
- Strategic activities by the market players, such as product launches, mergers and acquisitions, and partnerships, are expected to boost the demand for the metagenomics market. For instance, in December 2022, Evvy and MicroGenDX partnered to provide a standard of care for women's health with the CLIA-calidated, metagenomics-based vaginal health test. The Evvy Vaginal Health Test leverages mNGS to screen for every microbe isolated from the vaginal and urinary tract (excluding microbes related to reportable STIs).
- Therefore, owing to factors such as the wide adoption of metagenomics diagnostics and an increasing number of next-generation sequencing (NGS)-based research and technological advancements, the market for metagenomics is expected to drive in North America.
Metagenomics Industry Overview
The metagenomics market is moderately competitive and consists of a few major players. Some of the key players in the market are Illumina Inc., QIAGEN NV, Novogene Co. Ltd., PerkinElmer Inc., F. Hoffmann-La Roche Ltd., and Thermo Fisher Scientific Inc., among others.
Metagenomics Market Leaders
Illumina, Inc
PerkinElmer Inc.
QIAGEN N.V.
F. Hoffmann-La Roche Ltd
Novogene Co., Ltd
*Disclaimer: Major Players sorted in no particular order
Metagenomics Market News
- May 2023: Mainz Biome, a German biotech company, announced a significant research partnership with Microba Life Sciences, an Australian startup. The collaboration between these two entities is aimed at advancing scientific exploration in the realm of biotechnology. Within this partnership, Microba and Mainz Biome will jointly initiate a pilot research endeavor. The focus of this project involves leveraging Microba's pioneering metagenomic sequencing technology and advanced bioinformatic tools. The overarching goal of the endeavor is to uncover innovative and previously undiscovered microbiome biomarkers, particularly pertaining to the early detection of pancreatic cancer.
- February 2023: Microba Life Sciences Limited announced the successful launch of their advanced testing product line, MetaXplore, to healthcare professionals in Australia. This cutting-edge product range was introduced under the reimagined brand name, Co-Biome. The MetaXplore range offers an integrated approach by combining diagnostic assessments for gastrointestinal health with comprehensive metagenomic analysis of the gut microbiome. This innovation marks a significant step forward in healthcare diagnostics, offering a holistic perspective on individuals' well-being through the examination of both their gut health and microbiome composition.
Metagenomics Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing R&D Expenditure
4.2.2 Declining Expenses of Sequencing
4.2.3 Technological Advancements
4.3 Market Restraints
4.3.1 High Overall Cost of Metagenomics
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
5.1 By Product
5.1.1 Sequencing and Data Analytics Services
5.1.2 Kits and Reagents
5.1.3 Other Products
5.2 By Technology
5.2.1 Sequencing Driven
5.2.2 Function Driven
5.3 By Application
5.3.1 Human Health
5.3.2 Environmental
5.3.3 Other Applications
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Illumina Inc.
6.1.2 QIAGEN NV
6.1.3 Novogene Co. Ltd
6.1.4 PerkinElmer Inc.
6.1.5 F. Hoffmann-La Roche Ltd
6.1.6 Thermo Fisher Scientific
6.1.7 Promega Connections
6.1.8 Bio-Rad Laboratories Inc.
6.1.9 Merck KGaA
6.1.10 BGI Group
6.1.11 Eurofins Scientific
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Metagenomics Industry Segmentation
Metagenomics deals with the study in which it acts as a molecular tool that uses sequencing technologies and bioinformatics tools to analyze DNA acquired from environmental samples.
The metagenomics market is segmented by product (sequencing and data analytics services, kits, reagents, and other products), technology (sequencing driven and function-driven), application (human health, environmental, and other applications), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally.
The report offers the value (in USD) for the above segments.
| By Product | |
| Sequencing and Data Analytics Services | |
| Kits and Reagents | |
| Other Products |
| By Technology | |
| Sequencing Driven | |
| Function Driven |
| By Application | |
| Human Health | |
| Environmental | |
| Other Applications |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Metagenomics Market Research FAQs
What is the current Global Metagenomics Market size?
The Global Metagenomics Market is projected to register a CAGR of 12.60% during the forecast period (2024-2029)
Who are the key players in Global Metagenomics Market?
Illumina, Inc, PerkinElmer Inc., QIAGEN N.V., F. Hoffmann-La Roche Ltd and Novogene Co., Ltd are the major companies operating in the Global Metagenomics Market.
Which is the fastest growing region in Global Metagenomics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Metagenomics Market?
In 2024, the North America accounts for the largest market share in Global Metagenomics Market.
What years does this Global Metagenomics Market cover?
The report covers the Global Metagenomics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Metagenomics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Metagenomics Industry Report
Statistics for the 2024 Metagenomics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Metagenomics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
